(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 January 2013 (17.01.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/008171 A1

(51) International Patent Classification:
A61P 37/06 (2006.01) *C07K 16/28* (2006.01)
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/IB2012/053502

(22) International Filing Date:
9 July 2012 (09.07.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/506,491 11 July 2011 (11.07.2011) US

(71) Applicant *(for all designated States except US)*: **GLENMARK PHARMACEUTICALS S.A.** [CH/CH]; Chemin de la combeta 5, -, CH-2300 la chaux-de-fonds (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ATTINGER, Antoine** [CH/CH]; Chemin de la Combeta, 5, -, CH-2300 La Chaux-de-Fonds (CH). **BLEIN, Stanislas** [FR/CH]; Chemin de la Combeta, 5, -, CH-2300 La Chaux-de-Fonds (CH). **BACK, Jonathan Albert** [FR/CH]; Chemin de la Combeta, 5, -, CH-2300 La Chaux-de-Fonds (CH). **LISSILAA, Rami** [FR/CH]; Chemin de la Combeta, 5, -, CH-2300 La Chaux-de-Fonds (CH). **HOU, Samuel** [NZ/CH]; Chemin de la Combeta, 5, -, CH-2300 La Chaux-de-Fonds (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: ANTIBODIES THAT BIND TO OX40 AND THEIR USES

(57) **Abstract**: The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.

WO 2013/008171 A1